: BPC-157 ,
5-Amino-1MQ PM | 812 weeks on, 46 weeks off | General metabolic research, fat oxidation studies, insulin sensitivity protocols | Most balanced approach
MOTS-c is a cycled protocol, not a daily-for-life peptide
This phase is usually temporary, often resolving within 4-8 weeks as the skin completes its accelerated renewal cycle
Retatrutide is a more recently developed investigational compound a triple agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously
BPC-157 Mechanisms Researchers often discuss BPC-157 for its multi-layered protective functions across gastrointestinal, neuromuscular, vascular, and central nervous system tissues